Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13231025 | 0.91 | APP (0.33) | APP | |
| SCHEMBL4546740 | 0.86 | PTGS1 (0.35) | APPPTGS1PDE4ALMNASLC6A6 | |
| SCHEMBL14172469 | 0.81 | EPHX2 (0.42) | — | |
| SCHEMBL13403013 | 0.81 | FAAH (0.35) | — | |
| SCHEMBL14172470 | 0.80 | EPHX2 (0.33) | — | |
| SCHEMBL13133338 | 0.80 | BBOX1 (0.31) | — | |
| SCHEMBL12680246 | 0.79 | PTGS1 (0.30) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL13494362 | 0.79 | PTGS1 (0.30) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL13694506 | 0.78 | PTGS1 (0.33) | PTGS1PDE4A | |
| SCHEMBL13896267 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165877-A1 | ADMINISTRATION AND DOSAGE OF DIAMINOPHENOTHIAZINES | WISTA LABORATORIES LTD. (SG) | 2023-06-01 | — | — | US | disclosed |
| US-20230165876-A1 | METHYLTHIONINIUM COMPOUNDS FOR USE IN THE TREATMENT OF COVID-19 | WISTA LABORATORIES LTD. (SG) | 2023-06-01 | — | — | US | disclosed |
| US-8835500-B2 | Pharmaceutical formulations of amyloid inhibiting compounds | BHI Limited Partership (CA) | 2014-09-16 | — | — | US | disclosed |
| US-20090182056-A1 | PHARMACEUTICAL FORMULATIONS OF AMYLOID INHIBITING COMPOUNDS | BELLUS HEALTH INC. (CA) | 2009-07-16 | — | — | US | disclosed |
| US-20080027097-A1 | PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-01-31 | — | — | US | disclosed |
| US-7253306-B2 | Pharmaceutical drug candidates and methods for preparation thereof | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165876-A1 | METHYLTHIONINIUM COMPOUNDS FOR USE IN THE TREATMENT OF COVID-19 | ACE2, BHMT2, ICMT | APP 2614/4885PTGS1 1619/4885PDE4A 2653/4885 |
| US-20230165877-A1 | ADMINISTRATION AND DOSAGE OF DIAMINOPHENOTHIAZINES | ACHE, BCHE, PNMT | APP 111/4885PTGS1 3666/4885PDE4A 759/4885 |
| US-20080027097-A1 | PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | MPST, TTR, STS | APP 86/4885PTGS1 400/4885PDE4A 2979/4885 |
| US-20090182056-A1 | PHARMACEUTICAL FORMULATIONS OF AMYLOID INHIBITING COMPOUNDS | APP, TTR, BACE1 | APP 1/4885PTGS1 2641/4885PDE4A 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.